Publicaciones científicas

Twists and turns to translating 4-1BB cancer immunotherapy

12-jun-2019 | Revista: Science Translational Medicine

Miguel F Sanmamed, Iñaki Etxeberría, Itziar Otano, Ignacio Melero


Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al, this issue).

CITA DEL ARTÍCULO  Sci Transl Med. 2019 Jun 12;11(496):eaax4738. doi: 10.1126/scitranslmed.aax4738.